SpeeDx Recognised as Australian Company of the Year
SYDNEY, AUSTRALIA – (October 27, 2021). SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have been awarded Australian Company of the Year, received in the 2021 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards. Expert panel members aim to recognise companies and individuals representing Australia’s world-class biotechnology, medical technology, and healthcare sectors. The award recognises significant achievements of candidates including product pipeline, intellectual property, and company strategy.
SpeeDx sells over 45 products across multiple regions and regulatory jurisdictions based on over 80 patents protected globally. Already experiencing strong growth, the past year of the pandemic saw staff numbers increase by almost 50% to support an over 500% increase in production capacity. Supported by key investors the Northpond Ventures and Platinum International Health Care Fund, SpeeDx have pioneered an innovative approach to molecular diagnostics that supports data-driven treatment pathways in key areas of healthcare supporting antibiotic stewardship measures for infectious diseases, and personalised treatment practices in oncology.
“We are delighted to accept this prestigious award which recognises and celebrates the hard work and effort by the entire SpeeDx team during this past very challenging year, and indeed in the decade before,” said Adj/Prof Alison Todd, PhD FTSE, SpeeDx Chief Scientific Officer and co-founder. “SpeeDx is founded upon a simple mission to create accessible and clinically relevant diagnostic tools that empower clinicians with the information they need to improve patient care. We have applied our technology to support cancer patients, antibiotic stewardship in critical areas of sexual health, and more recently to address identification and understanding of COVID-19 and associated viral variants. As we grow, we build more resources and reach to apply our technology into new areas of need and continue to positively impact patient management around the world.”